Searched for
RATIOPHARM
Teva offers to buy Mylan for $40.1 billionTeva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement.- Jeremy Levin named as next CEO of Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries Ltd named Jeremy Levin of Bristol-Myers Squibb Coto to replace Shlomo Yanai as chief executive officer.
- Pharma group to oppose patent claimsA group of Indian pharmaceutical firms will collectively oppose as many as 90 drug patent applications sought by global drugmakers and some...
- Teva to buy Ratiopharm for nearly $5 bnIsrael's Teva has won the battle for German generic drugmaker Ratiopharm, paying an enterprise value of 3.63 billion euros to fix its weakn...
- EU officials raid Ranbaxy French unitRanbaxy's French unit has been raided by European antitrust officials as part of a probe on cozy drug settlements which allegedly delay the...
- Merckle family may sell Phoenix, Heidelberg stakesPhoenix Pharmahandel AG, the German drug wholesaler started by Adolf Merckle, may be put up for sale for as much as 6 bn euros ($7.8 bn) fo...
- German billionaire kills himself over financial crisisA German billionaire brought to the brink of ruin by the financial crisis has committed suicide, his family said on Tuesday.
- DRL, Ranbaxy, Wockhardt vie for German mega-dealThe bid is scheduled to open in the first week of November. Germany, which is the world’s second largest drug market, looks for ways to cur...
- Dr Reddy's could face margin pressure in GermanyLeading Indian drug makers with a large presence in Germany could face substantial pressure on margins following a recent tender by a Germa...
- Safe & steady strategy gives Cipla lead over RanbaxySome years ago, investors were hooked to Ranbaxy Labs’ growth story and the many earnings triggers that lay ahead.
Load More- Teva to buy Ratiopharm for nearly $5 bn
